Perception of abnormal serum prostate-specific antigen (PSA) test results amongst family practitioners

Annals of the Royal College of Surgeons of England

Volumn 90, Issue 5, 2008, Pages 398-402

  Rochester, M A ^a   Donaldson, P J ^a   McLoughlin, J ^a  

^a West Suffolk and Ipswich Hospitals ^*  (United Kingdom)

Author keywords

Primary care practice; Prostate cancer; PSA testing; Referral

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ARTICLE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; INFORMATION DISSEMINATION; MALE; PATIENT REFERRAL; PHYSICIAN ATTITUDE; PRIMARY MEDICAL CARE; PROSTATE CANCER; QUESTIONNAIRE; REFERENCE VALUE; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; CLINICAL COMPETENCE; EARLY DIAGNOSIS; FAMILY PRACTICE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUESTIONNAIRES; REFERRAL AND CONSULTATION;

EID: 48249157859     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588408X301019     Document Type: Article

References (16)

1. Cancer Research UK. CancerStats Incidence UK. London: Cancer Research UK, 2004.
2. Gavin A. McCarron P. Middleton RJ, Savage G, Catney D, O'Reilly D et al. Evidence of prostate cancer screening in a UK region. BJU Int 2004; 93: 730-4.
3. Jacobsen SJ, Katusie SK, Bergstralh EJ, Oesterling JE, Ohrl D, Klee GG et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 1995; 274: 1445-9.
4. Newcomer LM, Stanford JL, Blumenstein BA, Braweer MK. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol 1997; 158: 1427-30.
5. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993: 270: 860-4.
6. Carter HB, Pearson JD, Natter EJ, Brant LJ, Chan DW, Andres R et al. Longitudinal evaluation of proslate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20.
7. National Screening Committee. UK National Screening Committee's policy positions July 2006. London: Department of Health, 2006.
8. Brett J, Watson E, Hewilson P, Bukach C, Edwards A, Elwyn G et al. PSA testing for prostate cancer: an online survey of the views and reported practice of general practitioners in the UK. BMC Fam Pract 2005; 6: 24.
9. Mokete M, Shackley DC, Betts CD, O'Flynn K J, Clarke NW. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK. BJU Int 2006; 97: 266-9.
10. Lamplugh M, Gilmore P, Quinlan T, CornFord P. PSA testing: are patients aware of what lies ahead? Ann R Coll Surg Engl 2006; 88: 284-8.
11. Winkler M, Meyer E, Hughes H, Penny M, Carter A, Green J. Age-specific PSA reference values based on a screening population of British men. BJU Int 2006; 97 (Suppl 3): 4.
12. Weller D, May F, Rowell D, Esterman A, Pinnock C, Nicholson S et al. Promoting better use of the PSA test in general practice: randomized controlled trial of educational strategies based on outreach visits and mailout. Fam Pract 2003; 20: 655-61.
13. Melia J, Moss S. Survey of the rate of PSA testing in general practice. Br J Cancer 2001; 85: 656-7.
14. Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 2004; 94: 51-6.
15. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for proslate cancer, section Rotterdam. J Urol 2005; 174: 121-5.
16. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL et al. Prevalence of prostate cancer among men with a prostate-specilie antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-4.